Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | FPR1 | P21462 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6557623 | 0.81 | KMT2A (0.38) | HPGDKMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL14491121 | 0.76 | CTSS (0.54) | CTSL | |
| SCHEMBL6847779 | 0.76 | CTSS (0.54) | CTSL | |
| SCHEMBL5445285 | 0.74 | ALDH1A1 (0.34) | HPGDKMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6742782 | 0.72 | CTSC (0.49) | HPGDCTSL | |
| SCHEMBL4430587 | 0.71 | ALPI (0.56) | HPGDSLC1A3SLC1A2SLC1A1ALDH1A1 | |
| SCHEMBL5445806 | 0.70 | ALDH1A1 (0.34) | HPGDKMT2ASLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6742769 | 0.70 | CTSC (0.47) | HPGDCTSL | |
| SCHEMBL6742169 | 0.70 | CTSC (0.47) | HPGDCTSL | |
| SCHEMBL8291801 | 0.70 | HPGD (0.48) | HPGDSLC1A3SLC1A2SLC1A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | claimed |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-14 | — | — | US | disclosed |
| US-7196099-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | HPGD 1476/4885KMT2A 4602/4885SLC1A3 3768/4885 |
| US-20070135386-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | HPGD 1476/4885KMT2A 4602/4885SLC1A3 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.